Pluristem Therapeutics Inc. (NasdaqCM: PSTI; TASE: PLTR) is a leading developer of placenta-based cell therapies. The company's patented PLX (PLacental eXpanded) cells drug delivery platform releases a cocktail of therapeutic proteins in response to a variety of local and systemic inflammatory diseases. PLX cells are grown using the company’s proprietary 3D micro-environmental technology and are an off-the-shelf product that requires no tissue matching or immune-suppression treatment prior to administration.Pluristem has announced that The Company's Sr. VP of Corporate Development, William Prather RPh, MD, will present at three upcoming financial and scientific events in the U.S.
According to the press release, "Dr. Prather will be "outlining the progress that Pluristem has made on the development of its PLacental eXpanded (PLX) cell product candidates," as well as speaking about "the recently announced pre-clinical data on acute radiation syndrome (ARS) and acute myocardial infarction (AMI), the construction of Pluristem's state-of-the-art cell therapy manufacturing facility, as well as the company's strategy of partnering with pharmaceutical companies for the marketing of several of its potential cell therapies."
Below is the schedule of events where Pluristem will be delivering presentations:
Needham Healthcare Conference - April 3 at 2:00PM - 2:40PM in Henry New York Palace Hotel, Manhattan, New York City
Imperial Capital's Healthcare Investor Forum - April 17 at 10:15AM - 10:45AM, New York Palace Hotel, Manhattan, New York City
8th Stem Cell Summit - April 19 at 3:15PM - 5:45PM session and on April 20 at 10:45AM - noon session, Hyatt Harborside Hotel, Boston, MA